Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

Amir Nashat

AddedMar 31, 2024

UpdatedMay 31, 2026

Amir Nashat

Amir Nashat

Board Member, Scholar Rock Holding

Amir Nashat's Career

Scholar Rock Holding

Scholar Rock Holding

Cambridge, MA, US

Board Member· Board

Morphic Therapeutic

Morphic Therapeutic

Waltham, MA, US

Board Member· Board

Paratus Sciences

Paratus Sciences

New York City, NY, US

CEO· C-Suite · Management

Kojin Therapeutics

Kojin Therapeutics

Cambridge, MA, US

Board Member· Board

WaveRx

Waltham, MA, US

Board Member· Board

Sofregen Medical

Sofregen Medical

Framingham, MA, US

Board Member· Board

Jnana Therapeutics

Jnana Therapeutics

Boston, MA, US

Board Member· Board

Dewpoint Therapeutics

Dewpoint Therapeutics

Boston, MA, US

Board Member· Board

AgBiome

Triangle (historical), NC, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Amir Nashat's Career

Scholar Rock Holding

Scholar Rock Holding

Public1142017Cambridge, MA, US

Board Member· Board

Leadership at Scholar Rock Holding

Jay BackstromCEO

David HallalBoard Member

Joshua ReedBoard Member

Srinivas AkkarajuBoard Member

Akshay VaishnawBoard Member

Similar to Scholar Rock Holding

Fulcrum TherapeuticsCambridge, MA, USPharmaceuticalsest. 2016Fulcrum TherapeuticsCambridge, MA, US · est. 2016

Fulcrum Therapeutics, Inc., a Cambridge-based company, develops and distributes transformative gene regulation drugs.

Public · $603.3M89

Solid BiosciencesCambridge, MA, USGene Therapy, Therapiesest. 2013Solid BiosciencesCambridge, MA, US · est. 2013

Solid Biosciences Inc., a US-based biotech firm, develops therapies and devices for muscular dystrophy.

Public · $441.3M87

Blueprint MedicinesCambridge, MA, USCancer Treatmentsest. 2008Blueprint MedicinesCambridge, MA, US · est. 2008

Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.

Public · $2.4B641

SphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Morphic Therapeutic

Morphic Therapeutic

Public$510.5M1022015Waltham, MA, US

Board Member· Board

Leadership at Morphic Therapeutic

Susannah GrayBoard Member

Timothy SpringerBoard Member

Praveen TipirneniBoard Member

Norbert BischofbergerBoard Member

Martin EdwardsBoard Member

Otello StampacchiaBoard Member

Similar to Morphic Therapeutic

Pliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124

MorphoceuticalsMarblehead, MA, USBiotechnologyest. 2020MorphoceuticalsMarblehead, MA, US · est. 2020

Morphoceuticals Inc.: Pioneering bioelectric solutions for limb regeneration in biotechnology.

Forward TherapeuticsPalm Beach Gardens, FL, USOral Therapiesest. 2022Forward TherapeuticsPalm Beach Gardens, FL, US · est. 2022

Forward Therapeutics: Innovating chronic inflammatory treatment through advanced oral immune therapies.

Series A · $50M2

VeraMorphMansfield, MA, USPharmaceuticalsest. 2017VeraMorphMansfield, MA, US · est. 2017

VeraMorph: Innovating polymer-based oral dosage technology in pharmaceuticals since 2017.

Angel · $225k2

Paratus Sciences

Paratus Sciences

Series A$100M382021New York City, NY, US

CEO· C-Suite · Management

Similar to Paratus Sciences

Petri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

ProFound TherapeuticsCambridge, MA, USTherapeuticsest. 2022ProFound TherapeuticsCambridge, MA, US · est. 2022

ProFound Therapeutics: Innovating impactful disease understanding and therapeutic creation.

Series A · $75M35

Enavate SciencesNew York City, NY, USTechnology, Therapeuticsest. 2022Enavate SciencesNew York City, NY, US · est. 2022

Enavate Sciences: Investing in and fostering growth of innovative therapeutic tech firms.

Private Equity · $300M7

Faze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40

Kojin Therapeutics

Kojin Therapeutics

Series A$60M252020Cambridge, MA, US

Board Member· Board

Leadership at Kojin Therapeutics

Thomas CahillBoard Member

Vasanthi ViswanathanCo-Founder

Gini DeshpandeBoard Member

Benjamin CravattCo-Founder

Luba GreenwoodBoard Member

Stuart SchreiberCo-Founder

Similar to Kojin Therapeutics

Kovina TherapeuticsIndianapolis, IN, USAntiviral Therapeuticsest. 2020Kovina TherapeuticsIndianapolis, IN, US · est. 2020

Kovina Therapeutics: A preclinical biotech firm developing first-in-class antiviral therapies for HPV-related conditions.

Angel · $2.6M5

Kymera TherapeuticsWatertown, MA, USDrugsest. 2017Kymera TherapeuticsWatertown, MA, US · est. 2017

Kymera Therapeutics, a global biopharmaceutical firm, innovates drugs for untreatable acute and chronic diseases.

Public · $879M167

Z SquaredWexford, PA, USPharmaceuticalsest. 1996Z SquaredWexford, PA, US · est. 1996

Coeptis Therapeutics: Developing and acquiring pharmaceutical products through strategic partnerships.

Public · $11M10

Kinaset TherapeuticsMedfield, MA, USRespiratory Drugsest. 2020Kinaset TherapeuticsMedfield, MA, US · est. 2020

Kinaset Therapeutics develops novel respiratory drugs to address unmet medical needs.

Series A · $41.5M11

WaveRx

Pre-Seed$7.3M62004Waltham, MA, US

Board Member· Board

Leadership at WaveRx

Mark ColellaBoard Member

Scott RocklageBoard Member

Similar to WaveRx

WaveDyn VisionAlbuquerque, NM, USMedical Devicesest. 2019WaveDyn VisionAlbuquerque, NM, US · est. 2019

WaveDyn Vision: An innovative medical device company pioneering wavefront diagnostic technology.

WaveFront DynamicsAlbuquerque, NM, USMedical Devicesest. 2019WaveFront DynamicsAlbuquerque, NM, US · est. 2019

WaveFront Dynamics: Innovating vision care with advanced medical device technology.

Series A · $8M9

WaveclearErie, PA, USMedical Devicesest. 2013WaveclearErie, PA, US · est. 2013

WaveClear: A medical device startup innovating in ultrasonic therapies for occlusive vasculature.

Series A · $1.1M6

Waved MedicalOrono, ME, USMedical Devices, Risk AssessmentWaved MedicalOrono, ME, US

WAVED Medical provides image-based tech for breast care facilities to assess breast cancer risk.

Angel · $1.5k2

Sofregen Medical

Sofregen Medical

Series B$22.3M192014Framingham, MA, US

Board Member· Board

Leadership at Sofregen Medical

Paulina HillBoard Member

Anh HoangBoard Member

Jonathan HartmannBoard Member

Jenna AbelliCEO

Doug SheltonBoard Member

Jnana Therapeutics

Jnana Therapeutics

Series C$207M922016Boston, MA, US

Board Member· Board

Leadership at Jnana Therapeutics

Matthew HammondBoard Member

Brian CaliBoard Member

Donald NicholsonBoard Member

Joanne KotzCo-Founder

Joel BarrishCo-Founder

Carlo RizzutoBoard Member

Dewpoint Therapeutics

Dewpoint Therapeutics

Series C$287M1612018Boston, MA, US

Board Member· Board

Leadership at Dewpoint Therapeutics

Richard YoungCo-Founder

Giuseppe CiaramellaBoard Member

Ameet NathwaniCEO

Mark MurckoBoard Member

Jürgen EckhardtBoard Member

Olivier BrandicourtBoard Member

Similar to Dewpoint Therapeutics

Faze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40

Transition BioCambridge, MA, USDrug Discoveryest. 2020Transition BioCambridge, MA, US · est. 2020

Transition Bio: Pioneering biomolecular condensate analysis tech for precise drug discovery.

Series A · $50M50

DeepBiome TherapeuticsLlanura, MA, USDrug Discoveryest. 2017DeepBiome TherapeuticsLlanura, MA, US · est. 2017

DeepBiome Therapeutics, a US-based biotech firm, leverages deep learning and synthetic biology for innovative drug discovery.

Nereid TherapeuticsBoston, MA, USDrug Discoveryest. 2020Nereid TherapeuticsBoston, MA, US · est. 2020

Nereid Therapeutics: Innovating drug discovery with proprietary technologies for new disease treatments.

Series A · $50M12

AgBiome

Series D$252.5M1392012Triangle (historical), NC, US

Board Member· Board

Leadership at AgBiome

Scott UknesCo-Founder

John RyalsCo-Founder

Kristina BurowBoard Member

Paul Schulze-LefertCo-Founder

Marijn DekkersBoard Member

Alison LawtonBoard Member

Similar to AgBiome

Boost BiomesSouth San Francisco, CA, USBiological Productsest. 2016Boost BiomesSouth San Francisco, CA, US · est. 2016

Boost Biomes, Inc.: Innovating unique biological products through proprietary microbiome technology in the US.

Series A · $4.2M

Ascribe BioscienceIthaca, NY, USCrop Protectionest. 2017Ascribe BioscienceIthaca, NY, US · est. 2017

Ascribe Bioscience: Developing eco-friendly products to boost crop defenses against pathogens since 2017.

AgrynexIthaca, NY, USBiopesticides, Crop Protectionest. 2015AgrynexIthaca, NY, US · est. 2015

Agrynex: Providing biocidal enzymes for crop protection against soil-borne diseases.

Pivot BioBerkeley, CA, USAgricultural Productsest. 2010Pivot BioBerkeley, CA, US · est. 2010

Pivot Bio, Inc.: A US-based AgriTech firm innovating plant nutrition by harnessing atmospheric nitrogen.

Series D · $616.9M488

Amir Nashat's Similar Executives & Operators

Lau Eng BoonBoard Member · Bukalapak

Willix HalimCEO · Bukalapak

Achmad ZakyCo-Founder · Bukalapak

Nugroho HerucahyonoCo-Founder · Bukalapak

Jay Geoffrey WacherBoard Member · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

Bo ZhangCo-Founder · DiDi

WILL WEI CHENGBoard Member · DiDi

People Similar to Amir Nashat

Ken EhrhartCo-Founder · Equitek Capital

Savneet SinghBoard Member · PAR Technology

Ross JohnsonBoard Member · Parion Sciences

R. Bob SmithBoard Member · PAR

Scott SlinkerCo-Founder · Unomicedge

Dan RubinCEO · Parx Solutions